Yoshiko Kubo1,2, Tateaki Naito3, Keita Mori4, Gakuji Osawa5, Etsuko Aruga5. 1. Department of Palliative Medicine, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo, 173-8605, Japan. kawabehachi@yahoo.co.jp. 2. Department of Breast Surgery, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. kawabehachi@yahoo.co.jp. 3. Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. 4. Clinical Research Center, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. 5. Department of Palliative Medicine, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo, 173-8605, Japan.
Abstract
PURPOSE: The aim of this study was to clarify the changes in the cross-sectional area of skeletal muscle and muscle attenuation (MA) during 12-month period before death in breast cancer patients. METHODS: Breast cancer patients who received treatment between September 2002 and July 2014 at Shizuoka Cancer Center or between December 2005 and July 2014 at Teikyo University Hospital were identified. Computed tomography (CT) scans during the 12-month period before death of consecutive female patients who died of breast cancer were reviewed. Skeletal muscle quantity and quality were evaluated by a cross-sectional area of skeletal muscle and MA, respectively, on CT scans taken 10-12 months (T1), 7-9 months (T2), 4-6 months (T3), and within 3 months (T4) prior to death. Wilcoxon signed rank test was used to compare the differences between the two-time points with Bonferroni correction (p = 0.0083). RESULTS: The medical records of 99 patients (median age at death, 57 years; range, 40-83 years) were retrospectively analyzed. Both the cross-sectional area and MA continued to decrease during 12-month period before death. Statistically significant differences were observed in the cross-sectional areas between T1 and T4 (p = 0.0011), T2 and T4 (p = 0.0019), and T3 and T4 (p = 0.0026), as well as in MA between T2 and T4 (p = 0.0012) and T3 and T4 (p = 0.0061). CONCLUSIONS: These results suggest that both quantity and quality of the skeletal muscle continued to decrease during 12-month period before death in breast cancer patients.
PURPOSE: The aim of this study was to clarify the changes in the cross-sectional area of skeletal muscle and muscle attenuation (MA) during 12-month period before death in breast cancerpatients. METHODS:Breast cancerpatients who received treatment between September 2002 and July 2014 at Shizuoka Cancer Center or between December 2005 and July 2014 at Teikyo University Hospital were identified. Computed tomography (CT) scans during the 12-month period before death of consecutive female patients who died of breast cancer were reviewed. Skeletal muscle quantity and quality were evaluated by a cross-sectional area of skeletal muscle and MA, respectively, on CT scans taken 10-12 months (T1), 7-9 months (T2), 4-6 months (T3), and within 3 months (T4) prior to death. Wilcoxon signed rank test was used to compare the differences between the two-time points with Bonferroni correction (p = 0.0083). RESULTS: The medical records of 99 patients (median age at death, 57 years; range, 40-83 years) were retrospectively analyzed. Both the cross-sectional area and MA continued to decrease during 12-month period before death. Statistically significant differences were observed in the cross-sectional areas between T1 and T4 (p = 0.0011), T2 and T4 (p = 0.0019), and T3 and T4 (p = 0.0026), as well as in MA between T2 and T4 (p = 0.0012) and T3 and T4 (p = 0.0061). CONCLUSIONS: These results suggest that both quantity and quality of the skeletal muscle continued to decrease during 12-month period before death in breast cancerpatients.
Entities:
Keywords:
Breast cancer; Cancer cachexia; Computed tomography; Muscle attenuation; Skeletal muscle; The cross-sectional area of skeletal muscle
Authors: Drazena Srdic; Sanja Plestina; Ana Sverko-Peternac; Nora Nikolac; Ana-Maria Simundic; Miroslav Samarzija Journal: Support Care Cancer Date: 2016-05-28 Impact factor: 3.603
Authors: Kenneth Fearon; Florian Strasser; Stefan D Anker; Ingvar Bosaeus; Eduardo Bruera; Robin L Fainsinger; Aminah Jatoi; Charles Loprinzi; Neil MacDonald; Giovanni Mantovani; Mellar Davis; Maurizio Muscaritoli; Faith Ottery; Lukas Radbruch; Paula Ravasco; Declan Walsh; Andrew Wilcock; Stein Kaasa; Vickie E Baracos Journal: Lancet Oncol Date: 2011-02-04 Impact factor: 41.316
Authors: Lisa Martin; Laura Birdsell; Neil Macdonald; Tony Reiman; M Thomas Clandinin; Linda J McCargar; Rachel Murphy; Sunita Ghosh; Michael B Sawyer; Vickie E Baracos Journal: J Clin Oncol Date: 2013-03-25 Impact factor: 44.544
Authors: Carla M M Prado; Vickie E Baracos; Linda J McCargar; Tony Reiman; Marina Mourtzakis; Katia Tonkin; John R Mackey; Sheryl Koski; Edith Pituskin; Michael B Sawyer Journal: Clin Cancer Res Date: 2009-04-07 Impact factor: 12.531
Authors: Carla M Prado; Michael B Sawyer; Sunita Ghosh; Jessica R Lieffers; Nina Esfandiari; Sami Antoun; Vickie E Baracos Journal: Am J Clin Nutr Date: 2013-08-21 Impact factor: 7.045
Authors: Carla M M Prado; Jessica R Lieffers; Linda J McCargar; Tony Reiman; Michael B Sawyer; Lisa Martin; Vickie E Baracos Journal: Lancet Oncol Date: 2008-06-06 Impact factor: 41.316
Authors: Jessica R Lieffers; Marina Mourtzakis; Kevin D Hall; Linda J McCargar; Carla M M Prado; Vickie E Baracos Journal: Am J Clin Nutr Date: 2009-02-25 Impact factor: 7.045
Authors: David P J van Dijk; Maikel J A M Bakens; Mariëlle M E Coolsen; Sander S Rensen; Ronald M van Dam; Martijn J L Bours; Matty P Weijenberg; Cornelis H C Dejong; Steven W M Olde Damink Journal: J Cachexia Sarcopenia Muscle Date: 2016-10-26 Impact factor: 12.910
Authors: Niklas Paul Grusdat; Alexander Stäuber; Marion Tolkmitt; Jens Schnabel; Birgit Schubotz; Henry Schulz Journal: Oncol Res Treat Date: 2021-10-13 Impact factor: 2.825
Authors: Guilherme Defante Telles; Miguel Soares Conceição; Felipe Cassaro Vechin; Cleiton Augusto Libardi; Marcelo Alves da Silva Mori; Sophie Derchain; Carlos Ugrinowitsch Journal: Front Physiol Date: 2022-06-16 Impact factor: 4.755
Authors: Thomas A Blackwell; Igor Cervenka; Bhuwan Khatri; Jacob L Brown; Megan E Rosa-Caldwell; David E Lee; Richard A Perry; Lemuel A Brown; Wesley S Haynie; Michael P Wiggs; Walter G Bottje; Tyrone A Washington; Byungwhi C Kong; Jorge L Ruas; Nicholas P Greene Journal: Physiol Genomics Date: 2018-10-05 Impact factor: 3.107
Authors: Niklas Paul Grusdat; Alexander Stäuber; Marion Tolkmitt; Jens Schnabel; Birgit Schubotz; Peter Richard Wright; Marc Heydenreich; Dirk-Henrik Zermann; Henry Schulz Journal: J Patient Rep Outcomes Date: 2022-02-21
Authors: Niklas Paul Grusdat; Alexander Stäuber; Marion Tolkmitt; Jens Schnabel; Birgit Schubotz; Peter Richard Wright; Henry Schulz Journal: Support Care Cancer Date: 2022-01-11 Impact factor: 3.359